Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Motzer RJ et al. · 2008 · Lancet · Atlas ID MOT2008

What this study shows

Everolimus extended median progression-free survival from 1.9 to 4.0 months versus placebo in metastatic renal cell carcinoma.

Abstract

ShowHide

Everolimus (RAD001) is an orally administered inhibitor of the mammalian target of rapamycin (mTOR), a therapeutic target for metastatic renal cell carcinoma. We did a phase III, randomised, double-blind, placebo-controlled trial of everolimus in patients with metastatic renal cell carcinoma whose disease had progressed on vascular endothelial growth factor-targeted therapy.

Read the full abstract on PubMed →

At a glance

Evidence type	H Human study Marked H because it is direct evidence from a human clinical trial or human cohort; the code names the kind of study, not its quality -- a small, well-run trial is still H.
Study type	2 - Human Clinical Trial
Model system	Humans, phase III RCT (RECORD-1)
Journal	Lancet
Year	2008
Peer reviewed	Yes
Record last updated	2026-08-22
Source	DOI 10.1016/S0140-6736(08)61039-9 · PMID 18653228

Extracted findings

Intervention	Everolimus (RAD001)
Target	mTORC1
Model	Human – phase III RCT (RECORD-1), metastatic renal cell carcinoma
Effect	Everolimus improved progression-free survival vs placebo after VEGF-targeted therapy failure (abstract excerpt truncated before full results)

In the Atlas

Cite this paper

ShowHide

Motzer, R. J., et al. (2008). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. https://doi.org/10.1016/S0140-6736(08)61039-9

@article{MOT2008,
  author       = {Motzer, R. J. and others},
  title        = {{Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial}},
  journal      = {Lancet},
  year         = {2008},
  doi          = {10.1016/S0140-6736(08)61039-9},
  note         = {PMID: 18653228},
}

Cite this Atlas record

The record is the Atlas's own work — the evidence label, the extracted findings and the links. It is cited as part of the dataset, not as the paper.

Barton, O. (2026). Oliver's mTOR Atlas (record MOT2008) [Data set]. https://mtor-atlas.org/study/MOT2008/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_MOT2008,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}, record MOT2008},
  howpublished = {Data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/study/MOT2008/},
  doi          = {10.5281/zenodo.22059963}
}